Cannabinoids in PLWHIV on Effective ART
Cannabinoids in People Living With HIV on Effective Antiretroviral Therapy: A Pilot Study to Assess Safety, Tolerability and Effect on Immune Activation
Sponsor: CIHR Canadian HIV Trials Network
Terminated
expiration of study product; end of study product availability
Other terminated trials from CIHR Canadian HIV Trials Network
Listed as NCT03550352, this PHASE2 trial focuses on HIV Infections and remains terminated or withdrawn. Sponsored by CIHR Canadian HIV Trials Network, it has been updated 9 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Not Yet Recruiting → Terminated
-
Sep 2021 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
Status: Unknown Status → Not Yet Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE2
▶ Show 4 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Oct 2019 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2018 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CIHR Canadian HIV Trials Network
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Tilray
- Université du Québec a Montréal
For direct contact, visit the study record on ClinicalTrials.gov .